期刊文献+

一种KRAS基因突变检测方法的建立及初步应用 被引量:2

Establishment of a method about detecting KRAS gene mutations and its application
下载PDF
导出
摘要 目的建立一种KRAS基因实时荧光定量PCR-Sanger测序突变检测方法,并初步探讨其临床应用价值。方法以KRAS基因热点突变区域12、13密码子为研究位点设计特异性扩增、测序引物,利用已知野生型、突变型样品以TA克隆技术构建相应质粒作为标准品,建立KRAS基因实时荧光定量PCR-Sanger测序突变检测方法,并进行方法学和应用评估。结果成功构建了KRAS基因12、13密码子野生型、突变型质粒。建立了KRAS基因实时荧光定量PCR-Sanger测序突变检测方法,该方法灵敏度高(9.39×101copies/uL),重复性好(实时荧光定量PCR部分批内、批间变异系数分别为1.60%、2.54%)。该法与传统Sanger测序法同时检测40例临床样品,结果符合率为100%。结论本研究成功建立了可用于临床样品检测的KRAS基因实时荧光定量PCR-Sanger测序突变检测方法。 Objective To establish a method about detecting KRAS gene mutations through Sanger sequencing combined with Real-time PCR and evaluate its clinical value. Methods A KRAS gene mutations detection method through Sanger sequencing combined with Real-time PCR was established with specific primers targeting the hotspot mutation region (codonl2 and codonl3), and wild-type plasmid and mutant plasmid were constructed as the standard samples. Then the performance and application of method were assessed. Results The standard plasmids were constructed successfully. A KRAS gene mutations detection method through Sanger sequencing combined with Real-time PCR was established successfully which owned high sensitivity (9.39 × 10^1 copies/uL) and good repeatability(intra-assay CV and inter-assay CV of the Real-time PCR were 1.60% and 2.54%, respectively). There was no difference between traditional Sanger sequencing and Sanger sequencing combined with Real-time PCR to detect KRAS gene mutations in 40 clinical samples. Conclusion The established mutation detection method through Sanger sequencing combined with Real-time PCR can be used in clinical samples to detect KRAS gene mutations.
出处 《分子诊断与治疗杂志》 2013年第1期21-25,共5页 Journal of Molecular Diagnostics and Therapy
关键词 KRAS 突变 基因测序 实时荧光定量PCR KRAS Mutation Gene sequencing Real-time PCR
  • 相关文献

参考文献7

二级参考文献140

共引文献117

同被引文献26

  • 1Jemal A, Thomas A, Murray T, et al. Cancer statistics[J]. CA Cancer J Clin, 2002, 52(1): 23-47.
  • 2Soulieres D, Greer W, Magliocco AM, et al. K-RAS mutation testing in the treatment of metastatic colorec- tal cancer with anti-EGFR therapies [ J ]. Curr Oncol, 2010, 17(1): s31-40.
  • 3Linardou H, Dahabreh I J, Kanaloupiti D, et al. As- sessment of somatic k-ras mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in ad- vanced non-small-cell lung cancer and metastatic colo- rectal cancer[J]. Lancet Oncol, 2005, 9(10): 962- 972.
  • 4Brink M, de Goeij AFPM, Weijenberg MP, et al. K- ras oncogene mutations in sporadic colorectal cancer in the Netherlands cohort study [ J ]. Carcinogenesis, 2003, 24(4) : 703-710.
  • 5Han J. Polymerase preference index[P]. WO Patent, 2012,100089.
  • 6Chang YS, Yeh KT, Chang TJ, et al. Fast simultane- ous detection of K-RAS mutations in colorectal cancer [J]. BMC Cancer, 2009, 9: 179.
  • 7Poehlmann A, Kuester D, Meyer F, et al. K-ras mu- tation detection in colorectal cancer using the Pyrose- quencing technique [ J ]. Pathol Res Pract, 2007, 203 : 489-497.
  • 8方桦,王兴元,王金万,张弘纲,冯奉仪,石远凯.300例结直肠癌肝转移患者的临床预后分析[J].中华肿瘤杂志,2009,31(3):220-222. 被引量:27
  • 9刘云鹏.2008年转移性结直肠癌个体化治疗进展回顾[J].中国癌症杂志,2009,19(6):406-408. 被引量:7
  • 10黄新,鞠海星,陈贵平,吴伟,李德川,孙文勇,张苏展.应用焦磷酸测序法检测进展期结直肠癌中K-ras基因点突变[J].中国临床保健杂志,2010,13(4):391-393. 被引量:4

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部